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Abstract 
 Glioblastoma Multiforme is a form of intracranial tumor that while only affecting 2-3 
people per 100,000 per year, has an extremely high death rate with only 30% of patients 
surviving after two years. While early detection can extend this survival rate, GBM tumors 
mimic other complications and make it very difficult to detect via magnetic resonance imaging 
or computed topography scans. Therefore, an alternative detection method has been developed 
by taking advantage of the cancer cell’s altered metabolism. This mutated metabolism results in 
GBM patients having abnormally high lactate and low glucose levels. 
 One method of continuously monitoring the low glucose levels of patients is through a 
biosensor. This study looks to observe the effectiveness of a titanium dioxide electrode with 
copper nanoparticles deposited on the surface. Nine electrodes were synthesized from small 
pieces of titanium foil to be used for experimentation. Using cyclic voltammetry in various 
electrolyte solutions, the electrode’s effectiveness at detecting glucose was analyzed. 
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1. Introduction 
Glucose is one of the most essential carbohydrates in humans, being one of the main 
energy sources in the body and a precursor to countless other important substances, such as 
starch and cellulose. As essential as it is in providing life in humans, it can also be a key 
component in detecting or monitoring certain diseases, such as the widely spread diabetes. 
Glucose levels can also be used in monitoring tumor levels, especially in the very rare, but very 
deadly form of brain cancer known as Glioblastoma Multiforme, or GBM. GBM is a Grade IV 
astrocytoma that originates in the star-shaped cerebrum cells called astrocytes that affects 2-3 
people per 100,000 per years with a 75% death rate within the first eighteen months (Stark, 
2005). Treatment of GBM usually ranges from radiotherapy to total removal of the tumor 
followed by treatment with a chemotherapy drug.  
It is essential that these tumors are identified as early as possible in order to increase 
survival rate. However, the most common forms of tumor recognition, magnetic resonance 
imaging and computed topography scans, may not always identify GBM due to how well the 
tumor mimics other complications; therefore, the patient may lose valuable time in detecting the 
tumor which may inevitably cost them their lives.  
However, tumor cells have an altered metabolism that results in the body having 
abnormally high lactate and low glucose levels. This leads to an alternative way to detect GBM 
tumors—glucose monitoring. One form of continuous glucose monitoring is through the use of a 
biosensor. This MQP will study the effectiveness of using a titanium dioxide electrode with 
copper nanoparticles as a non-enzymatic biosensor for the detection of glucose. In order to test 
efficiency, cyclic voltammetric analyses will be performed under various conditions to determine 
how well the electrode can detect glucose levels. 
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2. Background Chapter 
The purpose of this chapter is to further examine the role of glucose in the body and its 
role in diseases, especially the brain tumor, Glioblastoma Multiforme. Also discussed in this 
chapter are different methods of monitoring a person’s metabolite levels, both inside and outside 
of the body, including biosensors devices. Specifically, the focus of this work is on the use of 
titanium dioxide biosensors implanted directly into the body in order to monitor glucose levels in 
a patient. 
2.1 Glucose 
 A carbohydrate, or a saccharide, is a biological compound that consists of carbon, 
hydrogen, and oxygen. Carbohydrates are categorized by their complexity (a simple one chain 
monosaccharide versus a large polysaccharide), reactivity (reducing or oxidizing), number of 
carbons, and their carbonyl grouping. The most common carbohydrate is glucose, a simple sugar 
with the chemical formula of C6H12O6 found widely in both plants and animals. Fitting the 
previous categories, glucose is a simple monosaccharide, an aldohexose (or a six-carbon 
molecule containing an aldehyde group), and a reducing sugar (Reusch, 2013). Glucose exists in 
humans through three primary natural sources. The first is the consumption of plants, which use 
sunlight to convert water and carbon dioxide to glucose and oxygen through photosynthesis. The 
second is the breakdown of glycogen, a polysaccharide of glucose that is used as the main 
storage of glucose in the body. And the final method is through gluconeogenesis in the liver that 
creates glucose from non-carbohydrate sources when the supply of glycogen is consumed and 
glucose is not being provided through diet. 
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2.1.1 Role of Glucose in the Body 
Glucose is the main energy source for the brain and nervous system, being the main 
substrate in cells’ energy production cycles, such as the tricarboxylic acid cycle (also known as 
the Krebs cycle or the citric acid cycle) and the mitochondrial electron transport chain. Through 
glycolysis, the body takes glucose and breaks it down to pyruvate and coenzymes used for 
energy (such adenosine triphosphate (ATP) and reduced nicotinamide adenine dinucleotide 
(NADH)). Pyruvate is further broken down in the Krebs cycle to release more energy coenzymes 
to be converted to ATP in the mitochondrial electron transfer chain. 
Glucose also plays a role in synthesizing several other carbohydrates and important 
substances. In most animals, glucose is a pre-cursor to ascorbic acid, or vitamin C. Glucose can 
also bind to proteins or lipids in order to form glycoproteins or glycolipids. Adding glucose to 
these structures assist in folding to increase stability or can act as recognition sites (New World 
Encyclopedia, 2008). Also, the linkage glucose is essential in synthesizing other complex 
carbohydrates. 
2.1.2 Problems Caused by Glucose 
 While glucose is essential to human life, many complications can be attributed to glucose 
levels in the body. The most well-known disease caused by glucose levels is hyperglycemia, 
which is an excessive amount of glucose circulating in the blood stream. Hyperglycemia is most 
common in diabetes mellitus (DM), where the glucose level is high due to the lack of inulin 
being produced in the body (Type 1 DM) or the cells do not properly react to the insulin being 
produced (Type 2 DM). According to the American Diabetes Association, a person with a resting 
glucose concentration consistently in the range of 110-126 mg/dL (5.6-7 mmol/L), as opposed to 
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the healthy adult rest rate of 70-110 mg/dL (3.9-5.6 mmol/L), is considered hyperglycemic while 
a person over 126 mg/dL is considered diabetic (ADA, 2003).  
On the opposite hand, hypoglycemia occurs when the body experiences a shortage in 
glucose and consistently has a resting concentration level below 70 mg/dL (Chase, “Low Blood 
Sugar”). Since the brain heavily relies on a steady income of glucose, a slight reduction in mental 
effectiveness can be observed as soon as a person reaches the hypoglycemic range. Prolonged 
hypoglycemia can result in neuroglycopenia, where the neurons in the brain become 
nonfunctional due to the lack of glucose. 
Other diseases have been attributed to glucose that do not necessarily come from the 
levels of glucose. One example is von Gierke disease, or glycogen storage type I disease, where 
once glucose is converted to glycogen, it cannot be converted back for energy consumption, 
resulting in a buildup of glycogen in the liver and a shortage of glucose in the body (Haldeman-
Englert, 2013). Most of the previous conditions mentioned, can be counteracted by monitoring 
the amount of glucose in a person’s diet. However, monitoring glucose levels can also be 
beneficial to observing phenomena that occurs in the body, such as a cell metabolizing more 
glucose than normal—one common trait of malignant cancer cells, specifically in Glioblastoma 
Multiforme. 
2.2 Glioblastoma Multiforme 
 Glioblastoma Multiforme (GBM) is a form of intracranial tumor that is rare amongst 
people, but has rapid progression, a low survival rate, and mostly unknown etiology. GBM is a 
Grade IV astrocytoma that originates in the star-shaped cerebrum cells called astrocytes that 
affects 2-3 people per 100,000 per year with a 75% death rate within the first eighteen months 
(Stark, 2005). In a study in 2013, observing 1645 cases of GBM, 98.4% of the patients, mostly 
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males between the ages of 55-64, died. These cases included multiple different types of 
treatments from radiotherapy to gross total removal of the tumor (Dubrow, 2013). The standard 
treatment of GBM is initial radiotherapy, followed by gross total resection (often omitted in 
patients older than 70 years) followed by treatment with the alkylating oral chemotherapy drug 
temozolomide (Bleeker, 2012). Studies show that primary GBM tumors often recur within two 
centimeters of its original size after radiotherapy in 80-90% of patients. The introduction of 
temozolomide as a treatment in 2005 has increased overall survival from 12.1 to 14.6 months 
and increased the likelihood of two-year-survival from 10% to 26% (Bruce, 2014). As with most 
tumors, treatment is most effective when detected early. However, this is difficult due to the fact 
that GBM can only be identified by clinical neuroimaging and the tumor manifests with little 
evidence of precursors. A secondary form of the GBM tumor that arises from lower-grade 
gliomas, but these are less common, less aggressive, and appear mostly in younger patients.  
2.2.1 Detecting Glioblastoma Multiforme 
 Typically, patients with GBM present symptoms in some or all of three categories: focal 
neurological deficit, increased cranial pressure, and seizures. Focal neurological deficits are 
problems with brain, spinal, or nerve function that affects a specific location on the body, as 
opposed to a general nonfocal problem (i.e. loss of consciousness) (Dugdale, “Focal neurological 
deficits”). Focal neurological deficits can be demonstrated in paralysis of limbs or facial 
movements, loss of muscle control, or changes in mood, speech, hearing, and vision. Once these 
symptoms occur, the GBM tumor can only be detected through neurological imaging. 
 Magnetic resonance imaging (MRI) and computed topography (CT) scanning are the 
most commons way to identify GBMs, but do not always work. As stated before, GBM tumors 
have little evident malignant precursors and can form in as little as three months. Because of this, 
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CT scans may miss small tumors if the scan is conducted in the early ages of GBM growth. MRI 
scans are more adept at identifying small tumors; however, GBM tumors can often mimic other 
complications, such as abscess, and can go undetected and prolong recognition (Bruce, 2014). 
These flaws in MRI and CT scanning can cause a patient to lose vital time in diagnosing their 
condition. Therefore, it is essential to either improve these methods or to introduce a new form of 
imaging. 
2.3 Glioblastoma Multiforme Tumor Cells 
 In GBM tumor cells, several growth factor pathways are altered from normal brain cells. 
In 2010, GBM cancer cells were separated into four subtypes based on what gene was mutated: 
classical, mesenchymal, proneural, and neural. In classical GBM tumors, high levels of the 
surface protein EGFR (epidermal growth factor receptor) are found, which causes the cell to 
divide more rapidly. The tumor suppressor gene, NF1, is most commonly mutated in 
mesenchymal tumors and proneural tumors have mutated TP53 and IDH1 genes, which result in 
abnormal cell growth. The fourth subtype of GBM tumor, neural, had no one mutation that stood 
out more than the rest. These types also react differently to treatments, with classical having the 
highest survival rate after aggressive treatment, and proneural having roughly the same survival 
rate between aggressive and nonaggressive treatments (Evans, 2011). This information is vital to 
treating GBM, because it allows clinicians to know more about how to specifically treat this case 
and what to look for when identifying the tumor.  
2.3.1 Growth Factor Levels in GBM Cells 
 In GBM cancer cells, high levels of growth factors are observed. For example, the 
increased production of EGFR in classical GBM tumors can be monitored by the level of the 
growth factor, EGF, which binds to EGFR in order to promote cell division. Other growth factors 
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such as PDGF (platelet derived growth factor), VEGF (vascular endothelial growth factor), and 
IGF (insulin-like growth factor) are also found to be abnormally high in malignant GBM cells 
(ABTA, 2014). This is important in initially detecting a GBM tumor in a patient. If a growth 
factor blood test shows high amounts of EGF or the other growth factors, then the patient can be 
recommended for neurological imaging in order to be certain of the tumor. 
2.3.2 Metabolism in Healthy Cells 
 One of the most crucial characteristics of all cancer cells, GBM tumors included, is that 
they do not follow the same cellular metabolism as normal cells. As stated briefly in Chapter 
2.1.1, in healthy cells, glucose is converted to pyruvate through glycolysis, releasing two ATP 
and two NADH molecules. From here, the path of pyruvate is dependent on the amount of 
oxygen available. If oxygen is present, the cell undergoes respiration where pyruvate is 
converted to acetyl-CoA and acetyl-CoA enters the Krebs cycle which produces more energy 
cofactors (ATP, NADH, and reduced flavin adenine dinucleotide, FADH2) that enter the 
mitochondria for oxidative phosphorylation, ultimately producing an additional 34 ATP 
molecules. Since oxygen is vital in oxidative phosphorylation, this process cannot occur in 
anaerobic conditions. Healthy cells will take the pyruvate formed from glycolysis and convert it 
to lactate (or alcohol in plants and yeast) through fermentation. Fermentation produces a 
molecule of oxidized NAD which is recycled into the glycolysis stream, but no additional ATP 
(Gregory, “Cellular Respiration”). These metabolic pathways are shown in Figure 1. 
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Figure 1: Healthy cell metabolism in aerobic (respiration) and anaerobic (fermentation) conditions (Carter, “Microbial 
Metabolism”). 
Overall, in healthy cells, both pathways begin with glycolysis and 36 molecules of ATP are 
produced in the presence of oxygen and 2 molecules are produced in the absence of oxygen. 
2.3.3 Metabolism in Cancerous Cells  
Cancerous cells do not follow the same pathways as normal, healthy cells. Whether the 
tumor cell is in oxygen-rich or oxygen-deficient environments, it only follows fermentation 
pathway, as shown in Figure 2. 
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Figure 2: Comparison of cellular metabolism in aerobic and anaerobic conditions (Wickramasekera, “Cancer Cell 
Metabolism”). 
This removal of the normal aerobic pathway is the primary cause of cancer. Lactic acid 
fermentation is much less energetically efficient than aerobic respiration. Instead of the 36 ATP 
normally produced in oxygen-rich environments, only 2 ATP will be produced. However, lactic 
acid fermentation occurs about 100 times faster than oxidative phosphorylation and, 
consequentially, results in an abundancy of glycolysis byproducts. These byproducts can then be 
used in other biosynthesis pathways responsible for producing the building blocks necessary for 
assembling new cells, resulting in the rapid reproduction of cancerous cells (Wickramasekera, 
“Cancer Cell Metabolism”). As stated by in a lecture by Dr. Otto Warburg, “cancer…has 
countless secondary causes. But, even for cancer, there is only one prime cause. Summarized in a 
few words, the prime cause of cancer is the replacement of the respiration of oxygen in normal 
body cells by a fermentation of sugar…” (Warburg, 1956). This rapid rate of glycolysis and 
absence of oxidative phosphorylation is known as the Warburg effect. 
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 Since lactic fermentation occurs much more rapidly than oxidative phosphorylation, 
glucose is consumed and lactate is produced much quicker in cancerous cells than in healthy 
cells. This difference becomes greater depending on the malignancy of the tumor, as shown in 
Figure 3. 
 
Figure 3: Glucose consumption in tumors of varying degrees of malignancy (Carter, “Microbial Metabolism”). 
Since Glioblastoma Multiforme is a grade IV tumor, it is considered extremely malignant. 
Therefore, GBM cells would be able to be detected in patients who exhibit the symptoms 
mentioned in Chapter 2.2.1, the growth factor levels mentioned in Chapter 2.3.1, and most 
importantly, the low glucose and high lactate levels discussed in this chapter. 
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2.3.4 Glucose and Lactate Levels in GBM Cells 
 The large difference in glucose and lactate levels between healthy and cancerous cells 
can be vital in identifying and treating patients with GBM. As stated in Chapter 2.1.2, the normal 
resting level of glucose is in the range of 3.9-5.6 mmol/L, while the normal resting level of 
lactate is in the range of 0.5-2.2 mmol/L (Dugdale, “Lactic acid test”). Patients with GBM 
tumors can have lactate levels as high as 40 mmol/L (Hirschhaeuser, 2011) and glucose levels 
between 1 and 2 mmol/L (Jiao, 2014). Since glucose is the prerequisite in lactic acid 
fermentation, it is especially vital in monitoring GBM tumors. Glucose can be controlled through 
diet and the effect of low-glucose diets has become a key focal point of GBM treatment 
(Jelluma, 2006; Champ, 2014). In the Jelluma et al. study, it was concluded that while glucose 
withdrawal usually results in lowered ATP production in most astrocytes, it actually increased 
ATP production in GBM patients. Overall, monitoring glucose levels can be very effective at 
monitoring the progression of the tumor. 
2.4 Monitoring Glucose Levels in the Body 
 Due to the fact that high glucose levels accelerate the progression of glioblastoma 
growth, it is imperative that patients monitor their glucose levels. Since diabetes is such a wide 
spread condition that also requires constant glucose monitoring, there are already many ways to 
go about this task. One method involves pricking one’s fingertip with a sharp needle and placing 
a drop of blood on a test strip. The test strip is then placed into a meter which gives results 
quickly. Newer meters allow the patient to use other test sites, such as one’s thigh, forearm, or 
upper arm. However, these areas are not as accurate as the fingertip, which shows changes more 
quickly—especially when levels are fluctuating such as during exercise or after eating. The 
newest method removes the need to continuously perform self-testing. Continuous glucose 
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monitoring (CGM) provides a nearly constant glucose level reading by monitoring the glucose 
concentration in the interstitial fluid between cells and sending the results to a handheld receiver. 
While CGM devices still need to be calibrated occasional through finger-sticking, it greatly 
reduces the hassle of monitoring glucose levels by letting the person just periodically glance at a 
device rather than perform a test (DHC, “How and When…”).  
2.4.1 Problems in CGM 
 A CGM device consists of three parts: the monitor, the transmitter, and the sensor. The 
monitor displays the readout, the sensor is inserted into the tissue beneath the skin, and the 
transmitter relays the information from the sensor to the readout. One problem with CGM 
devices is the tradeoff between high sensitivity and high specificity. Highly sensitive devices 
sound an alarm every time the glucose level is outside of the normal range. This is effective at 
ensuring the safety of the patient, but can often have false alarms. Highly specific devices have 
fewer false alarms, but can overlook some important occurrences (Yee, 2010). Therefore, 
manufacturers need to choose between tradeoffs when designing the device. 
2.4.2 Biosensors 
 The sensor in CGM devices is an example of a glucose biosensor. A biosensor is a 
compact analytical device made up of a transducer and a biological element that interacts with 
the desired analyte and relays the response via an electrical signal. The biological element can be 
an enzyme, a nucleotide, a protein, etc. and the transducer works in a physiochemical way to 
convert, or transduce, the signal resulting from the analyte interaction to a signal that can be 
quantified (Robertson, 2014). This concept is illustrated in Figure 4. 
20 
 
 
Figure 4: Illustration of how biosensors work (Andrews, 2011). 
The biological element of the biosensor recognizes and interacts with the desired analyte. The 
transducer then takes the signal received from the interaction (heat change, electron movement, 
etc.) and converts it to a measurable form. 
2.4.3 Glucose Biosensors 
Leland C. Clark is credited as the “father of biosensors” by publishing a paper on his 
oxygen electrode in 1956. The Clark electrode, as it was named, measured the activity of oxygen 
on a catalytic platinum surface. Clark wanted to find a way to make his electrode “more 
intelligent” by expanding its use to measuring analytes inside the body (Setford, 2005). In 1962, 
Clark added an inner oxygen semipermeable membrane, a thin layer or glucose oxidase (GOx), 
and an outer dialysis membrane. Using this “enzyme electrode,” as it was named, Clark found 
that the decrease in oxygen measured was proportional to the glucose concentration (Yoo, 2010).  
 The basic concept of glucose biosensors is that the GOx on the enzyme (along with a 
redox cofactor acting as the initial electron acceptor) catalyzes the oxidation of glucose by the 
following reactions: 
  Glucose + GOx(FAD) → Gluconolactone + GOx(FADH2)   (1) 
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  GOx(FADH2) + O2→ GOx(FAD) + H2O2    (2) 
The hydrogen peroxide then reacts with the platinum catalyst anode on the electrode, which 
releases two electrons. The sensor then uses the total electron flow to determine the glucose 
concentration. Succeeding glucose biosensors that followed this principle faced two main 
problems—restricted oxygen solubility in biological fluids and other species, such as ascorbic 
acid or uric acid, interfering with the electrons. In order to counteract the problems, “second-
generation” glucose biosensors changed to replace oxygen with redox mediators, such as 
ferrocenes, quinines, or thionines. These mediators formed reduced mediators other than 
hydrogen peroxide. Overall, the same general principle applied to both generations, but second 
generation sensors removed the problems associated with oxygen and hydrogen peroxide. 
Today’s biosensors are referred to as “third-generation” sensors and are attempting to become 
reagentless (to avoid high toxicity mediators) and directly transfer electrons from the enzyme to 
the electrode (Yoo, 2010). Due to the reduced toxicity, some of these biosensors can be 
implantable, such as the CGM devices previously mentioned. 
2.5 Implanted Glucose Biosensors 
 It has been generally described how biosensors interact with analytes in order to provide 
the necessary data; however, the materials used in the biosensors are vital to the success of the 
analyte detection—especially for biosensors implanted directly into the body. Since the 
discovery of biosensors, there has been little success in long-term implantable sensors. Overall, 
the main complications in long term use are: the body’s response to foreign bodies, the 
degradative effect of the proteases in the extracellular matrix on the biosensors, enzyme 
denaturation, changes in the membrane’s properties (such as density) due to time and 
temperature changes, and material failures (Kotanen, 2012).  
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2.5.1 Immune Response to Implanted Biosensors 
Implantation of these devices cause the body’s immune system to react through 
inflammation, blood clotting, and tissue contracting around the sensor. The body also responds 
by sending macrophages, platelets, and other defense mechanisms to the infection site that 
encapsulates and degrades the enzyme—this is known as biofouling. Biofouling serves as the 
main cause of the biosensor’s loss in sensitivity. Biofouling can cause the biosensor to see a 50-
80% decrease in sensitivity. The biofouling process is illustrated in Figure 5. 
 
Figure 5: Biofouling progress on the biosensor due to the body's immune system (Yun, 2009). 
The immune system’s first response is to send proteins, phospholipids, peptides, etc. to surround 
the biosensor. These proteins then interact with the cell, which produces tissue such as 
hemoglobin, albumin, and immunoglobulin to encapsulate the biosensor and prepare for attack of 
the phagocytic cells to degrade the biosensor (Yun, 2009). 
2.5.2 Problems with Enzymatic Biosensors 
 In enzyme-based biosensors, enzyme degradation poses as a huge threat to the success of 
the biosensor. Long term stability is one of the biggest problems with enzymatic glucose sensors, 
which, as stated before, typically use the enzyme glucose oxidase. While glucose oxidase is 
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relatively stable compared to most enzymes, it still faces the same problems—constant exposure 
to thermal and chemical deformation, changes in temperature, pH, and toxic chemicals, and 
changes in humidity levels. It has been observed that glucose oxidase loses its catalytic activity 
outside of the pH range of 2-8 or temperatures above 40°C (Park, 2006). While the normal pH 
level and temperature of the human body is 7.5 and 37°C, it can sometimes spike resulting in an 
environment that will denature glucose oxidase, ruining the biosensor’s efficiency. 
 Another problem with enzymatic biosensors is the difficulty in production. In order to 
attempt to preserve the enzyme’s catalytic ability for as long as possible, multiple enzyme layers 
must be placed on the electrode in a carefully optimized method called enzyme immobilization 
(Park, 2006). The quality of the sensors depends on the immobilization of the enzyme and 
therefore it is a difficult procedure to ensure the reproducibility of each biosensor. This is a great 
challenge, especially in mass manufacturing of the device. 
 A final problem with enzymatic biosensors is the presence of oxygen. Oxygen competes 
as an electron-mediating site and can affect the activity of the sensors (Park, 2006). Some 
enzymatic devices have attempted to solve this problem by having the electron transfer occur 
directly on the electrode surface (third generation biosensors).  
2.5.3 Non-enzymatic Biosensors 
In order to combat the problems associated with enzymes, non-enzymatic catalysts have 
been the focus of recent studies. Examples of non-enzymatic catalysts used in studies are metals 
such gold, platinum, and copper or polymer films such as polypyrrole (Cui, 2007; Ozcan, 2008). 
Each of these materials shows electrocatalytic activity towards the oxidation of glucose without 
the use of an enzyme.  
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However, while these approaches solve the problems faced by enzymatic devices, they 
are not completely problem-free on their own. One of the biggest issue with using metals, as 
opposed to enzymes, as an electrode is the occurrence of surface poisoning. While platinum was 
found to have one of the highest catalytic activities towards glucose oxidation, it is very 
susceptible to self-poisoning due to the absorption of carbon monoxide, chlorides, or other 
intermediates on the surface of the catalyst (Jin, 2007). In order to improve self-poisoning 
resistance, platinum was modified with heavy metals such as lead, bismuth, or tungsten trioxide 
(Kokkinidis, 1984; Wittstock, 1998; Zhang, 1997). However, this now introduces the problem of 
dissolution and toxins associated with these heavy metals which makes it impractical for in vivo 
usage. Heavy metal toxicity is a serious problem where the heavy metals interact with oxygen in 
the body and can affect normal enzymatic activity, which can affect nearly every organ system 
(Adal, 2014). Therefore, tradeoffs between catalytic activity and the ability to be used in the 
body must be considered. 
2.5.3 Titanium as a Glucose Biosensor 
 Titanium has been used in surgeries since the 1950s and is currently one of the most 
widely used metals in surgical implants. This is due to its high strength, low elastic modulus 
(very similar to that of actual bone) and, most importantly to implant use, high corrosion 
resistance and tissue compatibility (Wang, 1996). Also, since titanium is non-ferromagnetic, 
patients with titanium implants can still undergo neuroimaging such as MRI (NASS, “Magnetic 
Resonance Imaging”). This is imperative for patients with GMB who need to frequently monitor 
tumor growth. Due to all of these reasons, titanium is an ideal candidate for use as an 
implantable biosensor. 
25 
 
Many studies have already been conducted using titanium-based biosensors for glucose 
detection, both non-enzymatically (Cosnier, 1997; Ikeda, 1993; Khan, 1995) and for enzymatic 
stabilization (Rahman, 2010). Overall, titanium biosensors have been found to avoid the surface 
poisoning that most biosensor electrodes faced when using other metals. This results in the 
titanium biosensors lasting longer in the body without losing its catalytic activity. Titanium 
dioxide nanotubes were found to function as low as 5°C and as high as 50°C (Yin, 2010). This is 
covers a much greater range than enzymatic biosensors and easily functions within all 
biologically-possible temperatures within the human body. 
 The main focus of this study will be on the use of copper-deposited titanium oxide as an 
electrode in glucose detection. Cyclic voltammetry will be used in order to measure the catalytic 
activity between the electrode and the glucose solutions prepared. 
2.6 Conclusion 
 Glucose, being responsible for a vast majority of the energy production in cells, is one of 
the most important carbohydrates in the human body. While it is responsible for keeping the 
body alive, cancerous cells such as glioblastoma multiforme, can take advantage of the cell’s 
metabolism to result in a disease with a very low survival rate. It is essential to monitor GBM 
tumors through neuroimaging, such as MRIs and CT scans, and continuous glucose-level 
monitoring, which can be achieved by biosensors. While most biosensors use enzymes to detect 
the oxidation of glucose, difficulties in stability and other problems has resulted in a push for 
non-enzymatic biosensors that use modified metal or polymer electrodes. Titanium is an ideal 
candidate due to its excellent biocompatibility and will be used as the focus of this study. 
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3. Methodology 
The purpose of this chapter is to describe the methods used during this experimentation. 
This includes the synthesis of the titanium dioxide electrodes, the deposition of copper 
nanoparticles on the surface of the electrode, and descriptions of the procedures used to test the 
electrodes’ effectiveness at detecting glucose. 
3.1 Synthesis of Titanium Dioxide Electrodes 
 The first step in creating the titanium dioxide electrodes was to oxidize titanium foil into 
titanium dioxide. Small pieces of titanium foil (roughly one inch by one inch) were obtained 
from the laboratory as the starting material. To ensure that the surfaces of each foil piece was 
ideal, a thorough polishing process was followed. First, the titanium foil was polished by hand 
using polishing paper with varying grit sizes. Each side of the foil was polished for 30 minutes 
using 220 grit polishing paper, followed by 400 and 800 grit paper. This extensive polishing 
procedure ensured that the foil was as smooth as could be obtained by hand polishing and that 
there was no foreign material on the foil. 
 Following the hand polishing, the titanium foil was also chemically polished with acid. 
5mL of hydrofluoric acid was added to 15mL of nitric acid in a small beaker to form the strong 
acid solution to be used for polishing. This nitric-hydrofluoric acid solution is very common in 
industrial descaling of stainless steel and titanium. The titanium was submerged in the acid 
solution for 10 seconds until the solution turned a shade of yellow/orange and released a vapor of 
the same color. The titanium was then immediately submerged in deionized water, completing 
the polishing process and ensuring the highest current potential. 
 Following polishing, the titanium was anodized to synthesize the titanium oxide 
electrodes. Anodizing thickens the natural oxide layer on the surface of the metal, which would 
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form the titanium oxide electrode. The foil was anodized through potentiostatic anodization in an 
electrolytic solution. Some electrolytic solutions that can be used to anodize titanium are a 
dimethyl sulfoxide-hydrofluoric solution, a formamide-water/ammonium fluoride solution, or an 
ethylene glycol-ammonium fluoride solution (Shankar 2007). Shankar et al.’s work reported that 
using the ethylene glycol-ammonium fluoride solution resulted in the best nanotube array 
configuration; therefore, that was the best solution to use to anodize the titanium. The titanium 
anode was suspended in the electrolytic solution along with a small piece of platinum mesh to act 
as the cathode. The system was then attached to a power supply at 20 volts for one hour, 
continually being stirred by a magnetic stirrer set at a rotation speed of 190. After the 
anodization was complete, both the titanium dioxide electrode and the platinum mesh were 
washed with deionized water. Finally, the titanium was placed in a furnace set at 350°F for 1.5 
hours to complete the synthesis of the titanium dioxide electrode. 
3.2 Deposition of Copper Nanoparticles 
 It has been observed that depositing nanoparticles onto biosensors can improve its 
function. A study from 2009 looked at how nanoparticles effect can affect electrochemical 
biosensors (as well as optical and magnetic biosensors) and found that nanoparticles, such gold 
or platinum, can increase signal amplification, minimize noise interference, or increase 
sensitivity (Sanvicens 2009). Therefore, copper nanoparticles were deposited to the titanium 
dioxide electrode in order to increase the effectiveness of the biosensor. The nanoparticles were 
deposited through amperometric methods at two different conditions. A 15mL solution of 0.05M 
CuSO4/0.5M H2SO4 was prepared. Oxygen was removed from it by slowly bubbling nitrogen 
gas through the solution for 20 minutes. The titanium electrode was suspended with a platinum 
counter electrode and a reference electrode in the CuSO4/H2SO4 solution and was attached to a 
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galvanostat. An amperometric method was carried out through an Autolab computer program at 
two different operating conditions to see which method was optimal. The first set of electrodes 
was run at -0.4V for 220 seconds (Method 1) while the second set of electrodes was ran at -0.2V 
for 100 seconds (Method 2). Once the amperometry was complete, each copper-deposited 
electrode was rinsed with deionized water and dried with nitrogen gas. 
3.3 Cyclic Voltammetry Tests 
 To test the electrodes, cyclic voltammetry was used using same three-electrode 
configuration mentioned in the previous paragraph: the titanium dioxide foil as the reference 
electrode, platinum as the counter electrode, and the reference electrode provided with the 
galvanostat. Cyclic voltammetry measures the working electrode’s current while increasing the 
current to a set point and then decreasing the current back to the starting point. Different scan 
rates, potential ranges, and number of cycles can be set for each experiment. Since cyclic 
voltammetry was the primary source of measuring the electrode’s efficiency, the analysis was 
performed at every step of the process. 
Before the copper nanoparticles were deposited on the titanium dioxide electrode, a 
cyclic voltammetric analysis was performed on the pure electrode. A 15mL 0.01M phosphate 
buffered saline (PBS) solution was prepared and bubbled with nitrogen gas for 20 minutes prior 
to use as the electrolyte in this analysis. The three electrodes were suspended in the PBS buffer 
and cyclic voltammetry was performed at a potential range of -1.4 to 0.3V at a scan rate of 0.05 
V/s for 5 cycles. The same experiment was performed for the copper-deposited electrodes. In 
addition to testing the copper-deposited electrodes in the PBS buffer, the experiment was 
repeated using 0.1M NaOH that was bubbled with nitrogen as the electrolyte. These experiments 
were used to determine which copper-deposited titanium dioxide electrodes were the most 
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suitable to be used for glucose detection. Those electrodes were then repeated at scan rates of 
0.01, 0.03, 0.05, 0.07, and 0.09 while holding the potential range constant in order to ensure that 
each electrode followed the expectation that the magnitude of the current peaks should increase 
with increasing scan rates. This expectation is shown by the Randles-Sevcik equation, ip = 
268,600*n
3/2
*A*D
1/2
*C*v
1/2
 (where ip and v represent the current peak and the scan rate; other 
variables represent the number of electrons transferred (n), the electrode area (A), the diffusion 
coefficient (D), and the concentration (C)). 
3.4 Testing Glucose Detection 
 The next step after the ideal electrodes were determined was to experiment on the 
electrodes’ ability to detect glucose began. This analysis was also performed through cyclic 
voltammetry using the same three-electrode system as mentioned before; however, instead of a 
pure electrolyte solution of PBS or NaOH, a glucose-NaOH solution was used. A 1mM glucose-
0.1M NaOH solution was prepared for the first set of experimentation. The cyclic voltammetric 
analysis was then carried out at potential ranges of -0.8 to 0.3V and -0.6 to 0.4V. Each trial was 
conducted three times in order to ensure reproducibility. A large peak in the cyclic voltammetric 
graph would represent the electrode detecting the oxidation of glucose.  
A more diluted glucose-NaOH solution was prepared for the next round of 
experimentation, this time using 0.5mM glucose. The same procedure was repeated, running the 
cyclic voltammetry three times atpotential ranges of -0.8 to 0.3V and -0.6 to 0.4V. By decreasing 
the concentration of glucose in the glucose-NaOH solution, the magnitude of the current peaks 
would be expected to decrease since less glucose is there to oxidize and be detected by the 
electrode. This expectation also corresponds with the Randles-Sevcik equation.  
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The final experiment performed aimed to directly see the effect increasing the glucose 
concentration had on the magnitude of the current peak. Three NaOH solutions were prepared 
and bubbled with nitrogen—one containing no glucose, one with 1mM glucose, and one with 
5mM glucose. The cyclic voltammetric analysis was performed in succession using each of the 
three solutions (rinsing with deionized water between each trial) at a potential range of -0.2 to 
0.8V. This final experiment would show the correlation between the magnitude of the current 
peak and the concentration on a single plot and, ultimately, the electrodes effectiveness at 
detecting glucose. 
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4. Results and Discussion 
This objective of this study was to develop a copper-deposited titanium dioxide electrode 
that could be used as a biosensor for patients in need of continuously monitoring their glucose 
levels. In order to analyze the effectiveness of the electrode, multiple cyclic voltammetry and 
amperometry experiments were conducted on the electrodes in different electrolyte solutions. 
This chapter will report the results from the aforementioned experiments. 
4.1 Synthesis of Titanium Dioxide Electrode 
The first step in developing a method for monitoring of glucose level inside of a person 
was the creation of the titanium oxide electrode. Following the synthesis of titanium dioxide 
nanostructures on titanium foil through anodic oxidation, nine pieces of the titanium foil 
electrode were synthesized. To ensure that each electrode was developed as expected, 
electrochemical analysis was performed on each foil piece. They cyclic voltammetric scans for 
each of the nine titanium dioxide pieces can be seen below in Figure 6. 
 
Figure 6: Cyclic voltammetric scan of each of the nine synthesized titanium electrodes in 0.01M PBS buffer. 
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The main objective in analyzing each of the nine pieces was to ensure that none of the pieces 
differed drastically from the rest of the electrodes. As it can be seen in the figure, each of the 
nine scans adapted the same general shape, although the magnitude of the peak currents differed 
slightly. Since each scan resulted in the same shape, it can be inferred that the anodization 
process was generally successful, with a few exceptions. 
The main discrepancy amongst the scans is that four of the electrodes (the purple, lime 
green, and innermost red and blue curves) have cathodic current peaks at about 0.2V less than 
the other five scans. This inconsistency can be explained due to a change in the counter electrode 
during the voltammetric analysis. During experimentation, the original platinum mesh (that was 
used in the four scans mentioned above) broke and became unusable. This mesh was replaced 
with a platinum coil that was used as the counter electrode for the remaining five experiments. 
Although the electrode changed, the scans were still similar enough to each other to believe that 
all nine pieces were suitable to be used in further experimentation.  
4.2 Deposition of Copper Nanoparticles 
Once all nine titanium electrodes were determined to be appropriate for additional 
testing, copper nanoparticles were deposited onto the nanostructures through amperometry. The 
copper nanoparticles were deposited onto three of the electrodes (chosen at random) for each of 
the two methods described in the Methodology chapter. The electrodes will be referred to as 
Electrodes 1-3 and Electrodes 4-6, for Methods 1 and 2, respectively. Following the deposition 
of the nanoparticles, another cyclic voltammetric analysis was conducted in 0.1M NaOH 
solution. The scans for each of the two methods can be seen in Figures 7 and 8 on the following 
page. 
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Figure 7: Cyclic voltammetric scan for copper-deposited titanium electrodes using Method 1 of deposition. 
 
 
Figure 8: Cyclic voltammetric scan for copper-deposited titanium electrodes using Method 2 of deposition. 
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Once again, both Figures 7 and 8 illustrate that the copper-deposited titanium electrodes 
maintained similarly shaped curves throughout the electrochemical analyses while the magnitude 
of the peak differs. Again, this validates the assumption that the copper nanoparticles were 
successfully deposited onto each of the six titanium pieces. However, since the cyclic 
voltammetric analyses were conducted at differing potential ranges (-0.2V to 0.8V for Method 1 
and -0.5V to 0.3V for Method 2), the two methods cannot be directly compared to each other. 
However, Figures 7 and 8 seem to suggest that the two methods would result in two uniquely 
shaped voltammetric curves, allowing for further analysis of which method results in the more 
superior glucose detection. 
4.3 Determination of Most Efficient Electrodes 
 Based on the experiments in pure NaOH and pure PBS, the nine electrodes were 
narrowed down to two candidates to be used for the remainder of the experiments. These 
electrodes (Electrodes 1 and 4) were based on which had the most prominent cathodic peaks in 
the prior cyclic voltammetric scans (Figures 7 and 8). Once the two ideal titanium electrodes 
were selected, a second cyclic voltammetric analysis was conducted. The goal of this analysis 
was to observe how the voltammetric scan of the electrodes reacted to varying the potential scan 
rate. In theory, the magnitude of both the anodic and cathodic current peaks should increase 
proportionally to the square root of scan rate, as shown by the Randles-Sevcik equation, ip = 
268,600*n
3/2
*A*D
1/2
*C*v
1/2
. Both Electrode 1 and Electrode 4 underwent the voltammetric 
analysis in 0.1M NaOH at a potential range of -0.8V to 0.3V while setting the scan rate to 0.01, 
0.03, 0.05, 0.07, and 0.09V/s. The results can be seen in Figures 9 and 10. 
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Figure 9: Cyclic voltammetric scan of Electrode 1 at varying potential scan rates. 
 
 
Figure 10: Cyclic voltammetric scan of Electrode 4 at varying potential scan rates. 
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As expected based on the Randles-Sevcik equation, the magnitude of the peaks increased as the 
potential scan rate increased. This demonstrated that the electrochemical properties of Electrode 
1 and Electrode 4 were behaving as would be predicted by the theory behind the 
electrochemistry.  
4.3.1 Electrode Stability Issues 
Once the ideal two titanium electrodes were selected, no further experimentation was 
conducted for approximately twelve days. Following that short break, the same experimentation 
depicted in Figures 9 and 10 were repeated in order to compare results. These results can be seen 
in Figures 11 and 12. 
 
Figure 11: Cyclic voltammetric scan of Electrode 1 at varying potential scan rates after inactivity. 
37 
 
 
Figure 12: Cyclic voltammetric scan of Electrode 4 at varying potential scan rates after inactivity. 
The biggest observation amongst these Figures is the difference in voltammetric scans for 
Electrode 1, shown in Figures 9 and 11. After the inactivity, it appeared that Electrode 1 
completely lost its cathodic current peaks and almost entirely lost its anodic current peaks as 
well. Because of this, it became apparent that Electrode 1 could no longer be used for 
experimentation with glucose. There were two most likely reasons that this drastic change 
occurred. The first reason may be that the copper nanoparticles oxidized over time due to 
improper storage of the electrode or just overall poor deposition from Method 2. The second 
reason could be that the titanium dioxide nanostructures changed their structure over time which 
would be the fault of an imperfection during the synthesizing of the titanium electrode before the 
copper deposition. When looking at the voltammetric scan of Electrode 4, it can be seen that the 
change was much less drastic. While there was a slight change in the magnitude of the anodic 
and cathodic peaks, the shape generally remained the same. This ultimately allowed Electrode 
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4to be the only electrode synthesized that could be used in the further experimentation of glucose 
detection. 
4.4 Glucose Detection 
With an ideal electrode determined, the voltammetric analyses were no longer conducted 
in pure 0.1M NaOH or pure 0.01M PBS, but with glucose-NaOH solutions. The first electrolyte 
solution used was 1mM glucose in 0.1M NaOH. The cyclic voltammetric scan of Electrode 4 
was run in this solution at two different potential scan rates, -0.8V to 0.3V and -0.6V to 0.4V, 
three times in order to ensure stability and reproducibility. The results are shown in Figures 13 
and 14. 
 
Figure 13: Repeated Cyclic Voltammetric scan of Electrode 4 in 1mM Glucose-0.1M NaOH solution at -0.8V to 0.3V. 
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Figure 14: Repeated Cyclic Voltammetric scan of Electrode 4 in 1mM Glucose-0.1M NaOH solution at -0.6V to 0.4V. 
By running each scan three times and seeing the same scan each time, it was demonstrated that 
the electrode maintained its stability throughout the experiment. Figure 8 shows a noticeably 
greater magnitude of cathodic and anodic current peaks, reaching approximately 0.250x10
-2
 A 
and -0.700x10
-2
 A, respectively. These large peaks occur due to the reduction of glucose (or 
oxidation in the case of the anodic peak). These figures illustrate the fact that Electrode 4 
succeeds at detecting the oxidation and reduction of glucose when it is introduced into the 
solution, which is imperative when attempting to monitor glucose levels in patients. 
4.4.1 Complications in the Glucose Detection 
While the electrode did detect the glucose in the 1mM glucose-0.1M NaOH solution, 
some problems arose in the succeeding experiments involving the varying of the glucose 
concentration. The 1mM glucose solution was further diluted to 0.5mM glucose with 0.1M 
NaOH and cyclic voltammetry was repeated at the two potential ranges, again repeated three 
times each for reproducibility. The resulting scans can be seen in Figures 15 and 16. 
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Figure 15: Repeated Cyclic Voltammetric scan of Electrode 4 in 0.5mM Glucose-0.1M NaOH solution at -0.8V to 0.2V. 
 
Figure 16: Repeated Cyclic Voltammetric scan of Electrode 4 in 0.5mM Glucose-0.1M NaOH solution at -0.6V to 0.4V. 
If the electrode detected the glucose as expected, then increasing the concentration of glucose 
should also increase the magnitude of the current peak. This is proportional correlation is shown 
yet again by the Randles-Sevcik equation. However, as it can be seen in the two figures, this 
does not occur. By decreasing the concentration of glucose to 0.5mM, most of the peaks either 
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stay the same or actually increase in magnitude, as opposed to the expected result of 
approximately halving their peaks.  
One possible explanation to the phenomenon may be due to inaccurate dilution of the 
glucose-NaOH solution. In order to examine the possibility of this fault, new solutions were 
made from 10mM glucose and 0.1M NaOH. Once the new glucose solutions were made (this 
time 1mM and 5mM glucose), another cyclic voltammetric analysis was conducted in order to 
observe the behavior of increasing glucose concentration. These glucose concentrations were 
chosen to observe the effect of a five-fold increase in concentration as opposed to the two-fold 
increase in concentration used before. The analysis was run at a new potential scan rate in order 
to account for any abnormalities that may have occurred as a result of the low potentials. The 
result is seen in Figure 17. 
 
Figure 17: Cyclic voltammetric scan of Electrode 4 in varying glucose concentrations. 
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Once again, the expected trend is that increasing the glucose concentration would increase the 
current peak. However, as it can be seen, the cathodic peak stays roughly the same while the 
anodic peak decreases when the glucose concentration is increased. While this nullifies the claim 
that improperly made solutions caused the unpredicted trend, it brings forth the idea that the 
titanium electrode itself may have a defect that caused this occurrence.  
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5. Conclusions and Recommendations 
 The results in the previous section demonstrates that although the electrode did not react 
fully as expected in the detection of increasing glucose levels, many of the preliminary results 
were successful. Each of the 9 titanium foil pieces underwent the anodization and copper 
deposition processes and resulted in the expected formation of the titanium electrodes. The cyclic 
voltammetric experiments determined that Electrodes 1 and 4 were the most effective at 
developing strong cathodic and anodic current peaks. Once glucose was introduced into the 
electrolyte, the electrode also proved to be effective as detecting glucose, as could be seen by 
that change in peak between the pure NaOH electrolyte experiments and the glucose-NaOH 
electrolyte experiments. 
 However, while the electrode did succeed in detecting glucose, it did not follow the 
trends that the Randles-Sevcik equation predicted. Instead of the current peak increasing with the 
increasing concentration of glucose, the electrode acted inversely. Whether this was due to 
poorly formed electrodes or improperly made electrolyte solutions was not determined. Another 
issue that arose was the instability of the electrodes. Electrode 1 changed so drastically after 
inactivity that it could not be used for glucose detection; even the final electrode, Electrode 4, 
altered over the inactivity, although not nearly to the same extent as Electrode 1. 
 In continuing this research, there are three vital recommendations to follow in order 
ensure that electrodes work as expected. The first is to confirm that every electrolyte solution is 
made properly. Each of the solution made for this research were made by weighing out dry 
glucose and mixing it into aqueous NaOH or PBS solution to result in the desired concentration. 
However, human error may have been the cause for the results coming out not quite as expected.  
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The second recommendation is to perform each experiment over a shorter period of time. 
Due to time constraints, the entirety of the experiment was spread out over the course of more 
than three months, including a twelve day period of total inactivity. This time span may have 
caused the electrodes to lose their effectiveness over time. As an alternative to this 
recommendation, experimentation to increase the stability of these electrodes can also prove to 
be vital in developing effective electrodes. 
The final recommendation is to perform a greater number of glucose detection tests on 
the electrodes. The electrodes in this study were only tested in a few electrolyte solutions of 
differing glucose concentrations. By testing a wider range of glucose concentrations (as well as 
having more electrodes to test), it can be determined whether the trend found in the results of this 
study was a chance phenomenon or if every electrode would follow this same trend. This would 
result in an electrode that would be more effective at detecting low levels of glucose. 
There are alternative ways that continuous glucose monitoring can be studied. As 
mentioned before, different combinations materials and nanoparticles can be used as biosensor 
electrodes to affect the efficiency of detecting glucose. If titanium desired to be the main metal 
of interest, then different nanoparticles, such as gold or silver, can be deposited on the surface. 
Alternatively, different metals, such as platinum, can be studied to see how well it can be used to 
detect glucose. 
Overall, reducing human error, reducing inactivity, and increasing the number of 
experiments would all be very beneficial in determining whether or not copper-deposited 
titanium dioxide electrodes can efficiently be used as biosensors to aid in continuous glucose 
monitoring. However, regardless of the selectivity of the electrode towards glucose, many more 
tests must be done before it can be successfully used as an implantable biosensor. It is not 
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enough for the biosensor to detect glucose, but it needs to be able to be to remain stable in the 
conditions that are present in the human body to test if the conditions will affect the efficiency of 
the biosensor. Also, it needs to be ensured the body’s immune system will not attack and break 
down the biosensor too quickly. These in vivo requirements of the biosensor will also need to be 
tested once the selectivity towards glucose is at a desired level. 
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